nach oben

Current Hypertension Reports

Erschienen in:

01.02.2019 | Blood Pressure Monitoring and Management (John Cockcroft, Section Editor)

Personalized Medicine and the Treatment of Hypertension

verfasst von: Sarah Melville, James Brian Byrd

Erschienen in: Current Hypertension Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to discuss the implications of personalized medicine for the treatment of hypertension, including resistant hypertension.

Recent Findings

We suggest a framework for the personalized treatment of hypertension based on the concept of a trade-off between simplicity and personalization. This framework is based on treatment strategies classified as low, medium, or high information burden personalization approaches. The extent to which a higher information burden is justified depends on the clinical scenario, particularly the ease with which the blood pressure can be controlled.

Summary

A one-size-fits-many treatment strategy for hypertension is efficacious for most people; however, a more personalized approach could be useful in patients with subtypes of hypertension that do not respond as expected to treatment. Clinicians seeing patients with unusual hypertension phenotypes should be familiar with emerging trends in personalized treatment of hypertension.

GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–724. https://doi.org/10.1016/s0140-6736(16)31679-8.CrossRef

Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–90. https://doi.org/10.1016/s0140-6736(18)31694-5.CrossRefPubMedPubMedCentral

NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389(10064):37–55. https://doi.org/10.1016/s0140-6736(16)31919-5.CrossRef

Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165–82. https://doi.org/10.1001/jama.2016.19043.CrossRefPubMed

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–324. https://doi.org/10.1161/hyp.0000000000000066.CrossRefPubMed

Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. 2018;137(2):109–18. https://doi.org/10.1161/circulationaha.117.032582.CrossRefPubMed

Lip GY, Beevers M, Fau-beevers DG, Beevers DG. The ‘Birmingham Hypertension Square’ for the optimum choice of add-in drugs in the management of resistant hypertension. J Hum Hypertens. 1998;12(11):761–3. https://doi.org/10.1038/sj.jhh.1000688.

Liu X, Byrd JB, Rodriguez CJ. Use of physician-recommended non-pharmacological strategies for hypertension control among hypertensive patients. J Clin Hypertens (Greenwich). 2018;20(3):518–27. https://doi.org/10.1111/jch.13203.CrossRef

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–90. https://doi.org/10.1161/hyp.0000000000000084.CrossRefPubMed

10.

Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012. https://doi.org/10.1161/circulationaha.111.068064.

11.

Byrd J, Turcu A, Auchus R. Primary aldosteronism: practical approach to diagnosis and management. Circulation. 2018;138(8):823–835. https://doi.org/10.1161/CIRCULATIONAHA.118.033597

12.

•• Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015. https://doi.org/10.1016/s0140-6736(15)00257-3 This paper defines the current state of the art with respect to treatment of resistant hypertension.

13.

Hwang AY, Dave C, Smith SM. Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. Hypertension. 2016;68(6):1349–54. https://doi.org/10.1161/hypertensionaha.116.08128.CrossRefPubMed

14.

Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2009–20. https://doi.org/10.1056/NEJMoa1600175.CrossRefPubMed

15.

Schwalm JR, McCready T, Lamelas P, Musa H, Lopez-Jaramillo P, Yusoff K, et al. Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: the Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study. Am Heart J. 2018;203:57–66. https://doi.org/10.1016/j.ahj.2018.06.004.CrossRefPubMed

16.

Rydberg DM, Mejyr S, Loikas D, Schenck-Gustafsson K, von Euler M, Malmstrom RE. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. Eur J Clin Pharmacol. 2018;74(9):1165–73. https://doi.org/10.1007/s00228-018-2480-y.CrossRefPubMedPubMedCentral

17.

Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and beta-adrenergic blockers? A systematic review. BMC Med. 2013;11:141. https://doi.org/10.1186/1741-7015-11-141.CrossRefPubMedPubMedCentral

18.

Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71(4):681–90. https://doi.org/10.1161/hypertensionaha.117.10662.CrossRefPubMed

19.

•• Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA. 2018;320(6):566–79. https://doi.org/10.1001/jama.2018.10359 This paper shows that in some contexts, little personalization is required to achieve a benefit for patients.CrossRefPubMed

20.

Byrd JB. Personalized medicine and treatment approaches in hypertension: current perspectives. Integr Blood Press Control. 2016;9:59–67. https://doi.org/10.2147/ibpc.s74320.CrossRefPubMedPubMedCentral

21.

Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24(11):1164–80. https://doi.org/10.1038/ajh.2011.171.CrossRefPubMed

22.

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016:jc20154061. https://doi.org/10.1210/jc.2015-4061.

23.

•• Qi Y, Wang X, Rose KL, MacDonald WH, Zhang B, Schey KL, et al. Activation of the endogenous renin-angiotensin-aldosterone system or aldosterone administration increases urinary exosomal sodium channel excretion. J Am Soc Nephrol. 2016;27(2):646–56. https://doi.org/10.1681/asn.2014111137 This paper suggests the possibility of a mass spectrometry-based approach to predicting response to mineralocorticoid receptor antagonists.CrossRefPubMed

24.

•• Bazzell BG, Rainey WE, Auchus RJ, Zocco D, Bruttini M, Hummel SL, et al. Human urinary mRNA as a biomarker of cardiovascular disease. Circ Genom Precis Med. 2018;11(9):e002213. https://doi.org/10.1161/circgen.118.002213 This paper suggests the possibility of a pharmacotranscriptomic approach to predicting response to mineralocorticoid receptor antagonists.CrossRefPubMed

25.

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. https://doi.org/10.1056/NEJMoa1402670.CrossRefPubMed

26.

Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–70. https://doi.org/10.1016/s0140-6736(17)32281-x.CrossRefPubMed

27.

Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55. https://doi.org/10.1016/s0140-6736(18)30951-6.CrossRefPubMed

28.

Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–45. https://doi.org/10.1016/s0140-6736(18)31082-1.CrossRefPubMed

29.

Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J. 2015;36(40):2686–95. https://doi.org/10.1093/eurheartj/ehv392.CrossRefPubMed

30.

•• Laffin LJ, Besser SA, Alenghat FJ. A data-zone scoring system to assess the generalizability of clinical trial results to individual patients. Eur J Prev Cardiol. 2018:2047487318815967. https://doi.org/10.1177/2047487318815967 This is an innovative approach to determine how closely a patient resembles patients enrolled in the SPRINT trial.

31.

Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. https://doi.org/10.1056/NEJMoa1511939.CrossRefPubMed

32.

Byrd JB, Greene CS. Data-sharing models. N Engl J Med. 2017;376(23):2305. https://doi.org/10.1056/NEJMc1705477.CrossRefPubMed

33.

Zheutlin AR, Byrd JB. Opening opportunities with open data. JACC Heart Fail. 2018;6(6):530–2. https://doi.org/10.1016/j.jchf.2017.12.019.CrossRefPubMed

34.

•• Waljee AK, Sauder K, Patel A, Segar S, Liu B, Zhang Y, et al. Machine learning algorithms for objective remission and clinical outcomes with thiopurines. J Crohns Colitis. 2017;11(7):801–10. https://doi.org/10.1093/ecco-jcc/jjx014 This paper exemplifies a new generation of research focused on predicting drug response using machine learning models trained on commonly acquired laboratory data.CrossRefPubMedPubMedCentral

35.

McDonough CW, Magvanjav O, Sa ACC, El Rouby NM, Dave C, Deitchman AN, et al. Genetic variants influencing plasma renin activity in hypertensive patients from the PEAR study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018;11(4):e001854. https://doi.org/10.1161/circgen.117.001854.CrossRefPubMed

36.

•• Sa ACC, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, et al. Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genet. 2018;11(1):55. https://doi.org/10.1186/s12920-018-0370-x Reports the results of investigations into the pharmacogenetics of thiazide diuretics.CrossRef

37.

Cooper-DeHoff RM, Johnson JA. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol. 2016;12(2):110–22. https://doi.org/10.1038/nrneph.2015.176.CrossRefPubMed

38.

Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017;135(22):2091–101. https://doi.org/10.1161/circulationaha.116.024436.CrossRefPubMedPubMedCentral

39.

Knowles JW, Ashley EA. Cardiovascular disease: the rise of the genetic risk score. PLoS Med. 2018;15(3):e1002546. https://doi.org/10.1371/journal.pmed.1002546.CrossRefPubMedPubMedCentral

40.

•• Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in China and India: a microsimulation of target- versus risk-based blood pressure treatment. Circulation. 2016;133(9):840–8. https://doi.org/10.1161/circulationaha.115.019985 Models a risk-based approach for determining individuals’ blood pressure goals, constrasting with a treat-to-target approach.CrossRefPubMedPubMedCentral

41.

Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff DC Jr, Yusuf S, Zanchetti A, et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: a meta-analysis of individual participant data. PLoS Med. 2018;15(3):e1002538. https://doi.org/10.1371/journal.pmed.1002538.CrossRefPubMedPubMedCentral

42.

Araujo A, Julious S, Senn S. Understanding variation in sets of N-of-1 trials. PLoS One. 2016;11(12):e0167167. https://doi.org/10.1371/journal.pone.0167167.CrossRefPubMedPubMedCentral

Titel: Personalized Medicine and the Treatment of Hypertension
verfasst von: Sarah Melville
James Brian Byrd
Publikationsdatum: 01.02.2019
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 2/2019
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-019-0921-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Dietary Fat and Blood Pressure

Implementing Home Blood Pressure Monitoring into Clinical Practice

Real-World Strategies to Treat Hypertension Associated with Pediatric Obesity

Four-Limb Blood Pressure Measurement with an Oscillometric Device: a Tool for Diagnosing Peripheral Vascular Disease

Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis